Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy (original) (raw)

Cryptococcus gattii and Cryptococcus neoformans are significant human pathogens, particularly in immunocompromised individuals. The study explores the use of Chimeric Antigen Receptor (CAR) T-cell therapy targeting glucuronoxylomannan (GXM) in the Cryptococcus spp. capsule, demonstrating that GXMR-CAR T-cells recognize and activate against GXM, thereby enhancing anti-fungal immune responses. The findings suggest a novel therapeutic strategy for treating Cryptococcus infections, leveraging the specificity of CAR T-cells to improve outcomes in affected patients.